Efficacy and safety of dose-escalated alectinib in patients with metastatic ALK-positive NSCLC and CNS relapse on standard dose alectinib

被引：0
|
作者：
Cheung, Justin Matthew
Kang, Jiyoon
Yeap, Beow Y.
Peterson, Jenn
Do, Andrew
Digumarthy, Subba R.
Gainor, Justin F.
Lin, Jessica Jiyeong
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21079
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2016, 14 (06): : 241 - 243
  • [22] The Optimal ALK inhibitor in Advanced ALK-Positive NSCLC Patients: An Indirect Comparison Between Brigatinib and Alectinib
    Chen, G.
    Zhang, Y.
    Zhou, H.
    Zhao, S.
    Liu, J.
    Hong, S.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : S1056 - S1056
  • [23] Complete response to alectinib following crizotinib in an ALK-positive tumor with CNS involvement
    Xavier, Camila B.
    Canedo, Felipe S. N. A.
    Lima, Fabiola A. S.
    Melo, Raissa R.
    Lima, Luiz Guilherme C. A.
    Marin, Jose Flavio G.
    Souza, Ciro E.
    Feher, Olavo
    CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2021, 4
  • [24] Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
    Gadgeel, Shirish
    Shaw, Alice T.
    Barlesi, Fabrice
    Crino, Lucio
    Yang, James Chih-Hsin
    Dingemans, Anne-Marie C.
    Kim, Dong-Wan
    de Marinis, Filippo
    Schulz, Mathias
    Liu, Shiyao
    Gupta, Ravindra
    Kotb, Ahmed
    Ou, Sai-Hong Ignatius
    BRITISH JOURNAL OF CANCER, 2018, 118 (01) : 38 - 42
  • [25] Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
    Shirish Gadgeel
    Alice T Shaw
    Fabrice Barlesi
    Lucio Crinò
    James Chih-Hsin Yang
    Anne-Marie C Dingemans
    Dong-Wan Kim
    Filippo de Marinis
    Mathias Schulz
    Shiyao Liu
    Ravindra Gupta
    Ahmed Kotb
    Sai-Hong Ignatius Ou
    British Journal of Cancer, 2018, 118 : 38 - 42
  • [26] Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
    Garcia, Christine
    Abrahami, Devin
    Polli, Anna
    Chu, Haitao
    Chandler, Conor
    Tan, Min
    Kelton, John Mark
    Thomaidou, Despina
    Bauer, Todd
    CLINICAL LUNG CANCER, 2024, 25 (07) : 634 - 642
  • [27] Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib
    Gainor, Justin F.
    Sherman, Carol A.
    Willoughby, Kathryn
    Logan, Jennifer
    Kennedy, Elizabeth
    Brastianos, Priscilla K.
    Chi, Andrew S.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 232 - 236
  • [28] Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
    Peng, Ling
    Xiao, Kui
    Cui, Jian
    Ye, Xiang-Hua
    Zhang, Yong-Chang
    Mao, Li
    Selvaggi, Giovanni
    Yen, Jennifer
    Stebbing, Justin
    ONCOTARGETS AND THERAPY, 2021, 14 : 3409 - 3415
  • [29] Therapeutic effectiveness of Lorlatinib After Alectinib in Japanese Patients With ALK-Positive NSCLC in Real-World
    Goto, Y.
    Emir, B.
    Kaneyasu, K.
    Kikkawa, H.
    Wiltshire, R.
    Shukuya, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1084 - S1084
  • [30] Efficacy and safety study with alectinib in advanced ALK-positive non-small-cell lung cancer
    Fernandez Madrigal, Laura
    Garcia Samblas, Victoria
    Amor Urbano, Maria
    Inoriza, Angel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345